The GPI biosynthetic pathway as a therapeutic target for African sleeping sickness

M.A.J. Ferguson, J.S. Brimacombe, J.R. Brown, A. Crossman, A. Dix, R.A. Field, M.L.S. Güther, K.G. Milne, D.K. Sharma, T.K. Smith

Research output: Contribution to journalArticlepeer-review


African sleeping sickness is a debilitating and often fatal disease caused by tsetse fly transmitted African trypanosomes. These extracellular protozoan parasites survive in the human bloodstream by virtue of a dense cell surface coat made of variant surface glycoprotein. The parasites have a repertoire of several hundred immunologically distinct variant surface glycoproteins and they evade the host immune response by antigenic variation. All variant surface glycoproteins are anchored to the plasma membrane via glycosylphosphatidylinositol membrane anchors and compounds that inhibit the assembly or transfer of these anchors could have trypanocidal potential. This article compares glycosylphosphatidylinositol biosynthesis in African trypanosomes and mammalian cells and identifies several steps that could be targets for the development of parasite-specific therapeutic agents.

Original languageUndefined
Pages (from-to)327-340
Number of pages4
JournalBiochimica et Biophysica Acta - Molecular Basis of Disease
Issue number2-3
Publication statusPublished - 24 Sept 1999


  • Glycosylphosphatidylinositol
  • GPI
  • Trypanosome
  • Biosynthesis
  • Glycosyltransferase

Research Beacons, Institutes and Platforms

  • Manchester Institute of Biotechnology

Cite this